BTK and lymphoma: Indeed, a successful example of such an approach is the development of the dual PI3Kδ/CK1ε inhibitor Umbralisib, which has shown clinical efficacy in relapsed/refractory CLL and lymphomas, alone, or in combination with BTK inhibitors (45–47).